- Q2 2024 Novo Nordisk A/S Earnings Call TranscriptAug 07, 2024MXN2371.54 (-8.79%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 03, 2024MXN2150.39Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call TranscriptMay 02, 2024MXN2150.39Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2024
- Novo Nordisk A/S Capital Markets Day TranscriptMar 07, 2024
- Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 01, 2024MXN1823.1Earnings
- Q4 2023 Novo Nordisk A/S Earnings Call TranscriptJan 31, 2024MXN1823.1Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Novo Nordisk A/S at American Heart Association Conference TranscriptNov 11, 2023
- Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2023MXN1763.33Earnings
- Q3 2023 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2023MXN1763.33Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 11, 2023MXN1527.5 (-2.60%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call TranscriptAug 10, 2023MXN1568.22 (-0.43%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 26, 2023
- Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 09, 2023MXN1466 (-2.05%)Earnings
- Q1 2023 Novo Nordisk A/S Earnings Call TranscriptMay 04, 2023MXN1493.45Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 23, 2023
- Q4 2022 Novo Nordisk A/S Earnings Call TranscriptFeb 01, 2023MXN1327.8Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2022MXN1037Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2022MXN1037Earnings
- Novo Nordisk A/S at JPMorgan CEO Call Series TranscriptSep 14, 2022
- Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 05, 2022MXN1189.31Earnings
- Q2 2022 Novo Nordisk A/S Earnings Call TranscriptAug 03, 2022MXN1189.31Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA TranscriptJun 06, 2022
- Q1 2022 Novo Nordisk A/S Earnings Presentation - London TranscriptMay 05, 2022
- Q1 2022 Novo Nordisk A/S Earnings Call TranscriptApr 29, 2022MXN1159.77 (+6.03%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 24, 2022
- Novo Nordisk A/S Capital Markets Day TranscriptMar 03, 2022
- Q4 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 04, 2022MXN1012.33 (-6.54%)Earnings
- Q4 2021 Novo Nordisk A/S Earnings Call TranscriptFeb 02, 2022MXN996.27Earnings
- Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call TranscriptDec 20, 2021
- Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 04, 2021
- Q3 2021 Novo Nordisk A/S Earnings Call TranscriptNov 03, 2021MXN1059.43Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 06, 2021Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call TranscriptAug 04, 2021Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 28, 2021
- Novo Nordisk A/S Approval of Wegovy™ in the United States Investor Call TranscriptJun 07, 2021
- Novo Nordisk A/S to Discuss International Operations Call TranscriptMay 21, 2021
- Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 06, 2021Earnings
- Q1 2021 Novo Nordisk A/S Earnings Call TranscriptMay 05, 2021Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 25, 2021
- Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 05, 2021Earnings
- Q4 2020 Novo Nordisk A/S Earnings Call TranscriptFeb 03, 2021Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call TranscriptDec 16, 2020
- Novo Nordisk A/S ESG Conference Call TranscriptNov 30, 2020
- Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 02, 2020Earnings
- Q3 2020 Novo Nordisk A/S Earnings Call TranscriptOct 30, 2020Earnings
- Novo Nordisk A/S to Discuss Updated 2020 Outlook Call TranscriptOct 09, 2020
- Q2 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 07, 2020Earnings
- Q2 2020 Novo Nordisk A/S Earnings Call TranscriptAug 06, 2020Earnings
- Novo Nordisk A/S Virtual R&D Investor Call (Q&A) TranscriptJun 19, 2020
- Novo Nordisk A/S Virtual R&D Investor Presentation TranscriptJun 19, 2020
- Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2020
- Q1 2020 Novo Nordisk A/S Earnings Call TranscriptMay 06, 2020Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Q4 2019 Novo Nordisk A/S Earnings Presentation TranscriptFeb 06, 2020
- Q4 2019 Novo Nordisk A/S Earnings Call TranscriptFeb 05, 2020Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Novo Nordisk A/S Capital Markets Day TranscriptNov 20, 2019
- Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call TranscriptNov 18, 2019
- Q3 2019 Novo Nordisk A/S Earnings Presentation TranscriptNov 04, 2019
- Q3 2019 Novo Nordisk A/S Earnings Call TranscriptNov 01, 2019Earnings
- Novo Nordisk A/S to Discuss Rybelsus® US Approval Call TranscriptSep 23, 2019
- Q2 2019 Novo Nordisk A/S Earnings Presentation TranscriptAug 12, 2019
- Q2 2019 Novo Nordisk A/S Earnings Call TranscriptAug 09, 2019Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA 2019 TranscriptJun 10, 2019
- Q1 2019 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2019
- Q1 2019 Novo Nordisk A/S Earnings Call TranscriptMay 03, 2019Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2019
Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
/- -
I'm Lars Fruergaard Jørgensen. I'm the CEO of Novo Nordisk. And with me, I have Camilla Sylvest from Commercial; Martin from Medical; and Karsten, our CFO. So we'll do a quick introduction and just the theme by making a few presentations here. We will be talking about the future, which is inherently risky. So stay alert on the risk factors and our forward-looking statement here.
On strategic aspirations, we have set these aiming at delivering strong contribution to society, the environment, but of course, also our shareholders. So we see that based on these aspirations, and we believe we're making good progress. We have exciting progress from an innovation point of view. Martin will talk a bit to that, as we really focused on raising the bar in diabetes and obesity and expand into some adjacent disease areas.
You can see our commercial execution is really strong, strong growth in the first half year here, a continuation of an accelerated growth trend
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)